Bottom line
XLV vs VGHCX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and VGHCX (Vanguard Health Care Fund) share a meaningful slice of their top holdings — about 53% by weight.
XLV is cheaper at 0.08% vs 0.33% — a difference of $25 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +6.6% for VGHCX.
Updated Nov 19, 2026
XLV vs VGHCX side by side
| XLV | VGHCX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Vanguard |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.33% |
| Annual cost per $10k | $8 | $33 |
| 10-yr cost on $10k (prospectus) | $103 | $418 |
| Max front load | None | 0% |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +17.3% |
| 5-yr return (annualized) | +8.1% | +6.6% |
| 10-yr return (annualized) | +9.8% | +7.7% |
| Best quarter | +14.5% | +16.8% |
| Worst quarter | −12.7% | −12.3% |
| Net assets (fund) | $40.6B | $38.2B |
| Number of holdings | 65 | 97 |
| Portfolio turnover | 2% | 47% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | VGHCX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +17.3% | −2.8% |
| 2024 | +2.5% | −1.6% | +4.1% |
| 2023 | +2.0% | +5.4% | −3.4% |
| 2022 | −2.1% | −1.1% | −1.0% |
| 2021 | +25.9% | +14.3% | +11.6% |
| 2020 | +13.3% | +12.6% | +0.7% |
| 2019 | +20.7% | +22.9% | −2.3% |
| 2018 | +6.3% | +1.2% | +5.1% |
Source: Fund prospectus bar charts
Holdings overlap
14 of XLV's top 25 holdings also appear in VGHCX's top 25.
| Holding | XLV | VGHCX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 8.61% |
| Johnson & Johnson | 10.64% | 4.83% |
| AbbVie Inc | 7.74% | 2.30% |
| UnitedHealth Group Inc | 6.57% | 4.05% |
| Merck & Co Inc | 5.52% | 5.44% |
| Intuitive Surgical Inc | 2.45% | 2.52% |
| CVS Health Corp | 2.30% | 2.52% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.36% |
| Danaher Corp | 2.09% | 2.18% |
| Elevance Health Inc | 1.46% | 1.83% |
| Boston Scientific Corp | 1.10% | 1.53% |
| Regeneron Pharmaceuticals Inc | 1.08% | 2.14% |
| HCA Healthcare Inc | 1.05% | 1.68% |
| Cencora Inc | 0.96% | 2.47% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
VGHCX top 10
- Eli Lilly & Co — 8.61%
- Merck & Co Inc — 5.44%
- Johnson & Johnson — 4.83%
- AstraZeneca PLC — 4.59%
- UnitedHealth Group Inc — 4.05%
- Gsk Plc — 3.00%
- Edwards Lifesciences Corp — 2.56%
- Intuitive Surgical Inc — 2.52%
- CVS Health Corp — 2.52%
- Cencora Inc — 2.47%
FAQ
What is the difference between XLV and VGHCX?
Which is cheaper, XLV or VGHCX?
Should I own both XLV and VGHCX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.